103 related articles for article (PubMed ID: 28483279)
1. Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations.
Łepek T; Kwiatkowska A; Couture F; Ly K; Desjardins R; Dory Y; Prahl A; Day R
Eur J Cell Biol; 2017 Aug; 96(5):476-485. PubMed ID: 28483279
[TBL] [Abstract][Full Text] [Related]
2. Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors.
Kwiatkowska A; Couture F; Levesque C; Ly K; Beauchemin S; Desjardins R; Neugebauer W; Dory YL; Day R
ChemMedChem; 2016 Feb; 11(3):289-301. PubMed ID: 26751825
[TBL] [Abstract][Full Text] [Related]
3. Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue.
Dianati V; Navals P; Couture F; Desjardins R; Dame A; Kwiatkowska A; Day R; Dory YL
J Med Chem; 2018 Dec; 61(24):11250-11260. PubMed ID: 30501188
[TBL] [Abstract][Full Text] [Related]
4. Positional Scanning Identifies the Molecular Determinants of a High Affinity Multi-Leucine Inhibitor for Furin and PACE4.
Małuch I; Levesque C; Kwiatkowska A; Couture F; Ly K; Desjardins R; Neugebauer WA; Prahl A; Day R
J Med Chem; 2017 Apr; 60(7):2732-2744. PubMed ID: 28287731
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor.
Kwiatkowska A; Couture F; Levesque C; Ly K; Desjardins R; Beauchemin S; Prahl A; Lammek B; Neugebauer W; Dory YL; Day R
J Med Chem; 2014 Jan; 57(1):98-109. PubMed ID: 24350995
[TBL] [Abstract][Full Text] [Related]
6. Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines.
Dianati V; Kwiatkowska A; Couture F; Desjardins R; Dory YL; Day R
J Med Chem; 2018 Sep; 61(18):8457-8467. PubMed ID: 30180568
[TBL] [Abstract][Full Text] [Related]
7. Multi-Leu PACE4 Inhibitor Retention within Cells Is PACE4 Dependent and a Prerequisite for Antiproliferative Activity.
Couture F; Ly K; Levesque C; Kwiatkowska A; Ait-Mohand S; Desjardins R; Guérin B; Day R
Biomed Res Int; 2015; 2015():824014. PubMed ID: 26114115
[TBL] [Abstract][Full Text] [Related]
8. PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation.
Levesque C; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Neugebauer WA; Day R
Oncotarget; 2015 Feb; 6(6):3680-93. PubMed ID: 25682874
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug.
Kwiatkowska A; Couture F; Ait-Mohand S; Desjardins R; Dory YL; Guérin B; Day R
Sci Rep; 2019 Feb; 9(1):2118. PubMed ID: 30765725
[TBL] [Abstract][Full Text] [Related]
10. PACE4-based molecular targeting of prostate cancer using an engineered ⁶⁴Cu-radiolabeled peptide inhibitor.
Couture F; Levesque C; Dumulon-Perreault V; Ait-Mohand S; D'Anjou F; Day R; Guérin B
Neoplasia; 2014 Aug; 16(8):634-43. PubMed ID: 25220591
[TBL] [Abstract][Full Text] [Related]
11. Proprotein convertase inhibition: Paralyzing the cell's master switches.
Klein-Szanto AJ; Bassi DE
Biochem Pharmacol; 2017 Sep; 140():8-15. PubMed ID: 28456517
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of a Highly Potent and Selective Peptide Inhibitor of PACE4 by Salt Bridge Interaction with D160 at Position P3.
Dianati V; Shamloo A; Kwiatkowska A; Desjardins R; Soldera A; Day R; Dory YL
ChemMedChem; 2017 Aug; 12(15):1169-1172. PubMed ID: 28722823
[TBL] [Abstract][Full Text] [Related]
13. PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression.
Panet F; Couture F; Kwiatkowska A; Desjardins R; Guérin B; Day R
Eur J Cell Biol; 2017 Aug; 96(5):469-475. PubMed ID: 28347547
[TBL] [Abstract][Full Text] [Related]
14. The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.
Levesque C; Fugère M; Kwiatkowska A; Couture F; Desjardins R; Routhier S; Moussette P; Prahl A; Lammek B; Appel JR; Houghten RA; D'Anjou F; Dory YL; Neugebauer W; Day R
J Med Chem; 2012 Dec; 55(23):10501-11. PubMed ID: 23126600
[TBL] [Abstract][Full Text] [Related]
15. Engineering of alpha1-antitrypsin variants selective for subtilisin-like proprotein convertases PACE4 and PC6: importance of the P2' residue in stable complex formation of the serpin with proprotein convertase.
Tsuji A; Kanie H; Makise H; Yuasa K; Nagahama M; Matsuda Y
Protein Eng Des Sel; 2007 Apr; 20(4):163-70. PubMed ID: 17351018
[TBL] [Abstract][Full Text] [Related]
16. A proteomic approach reveals transient association of reticulocalbin-3, a novel member of the CREC family, with the precursor of subtilisin-like proprotein convertase, PACE4.
Tsuji A; Kikuchi Y; Sato Y; Koide S; Yuasa K; Nagahama M; Matsuda Y
Biochem J; 2006 May; 396(1):51-9. PubMed ID: 16433634
[TBL] [Abstract][Full Text] [Related]
17. Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.
Bassi DE; Zhang J; Cenna J; Litwin S; Cukierman E; Klein-Szanto AJ
Neoplasia; 2010 Jul; 12(7):516-26. PubMed ID: 20651981
[TBL] [Abstract][Full Text] [Related]
18. PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways.
Yao Z; Sun B; Hong Q; Yan J; Mu D; Li J; Sheng H; Guo H
Drug Des Devel Ther; 2015; 9():5911-23. PubMed ID: 26604689
[TBL] [Abstract][Full Text] [Related]
19. Role of proprotein convertases in prostate cancer progression.
Couture F; D'Anjou F; Desjardins R; Boudreau F; Day R
Neoplasia; 2012 Nov; 14(11):1032-42. PubMed ID: 23226097
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of PACE4 in prostate cancer is not dependent on E2F transcription factors.
Bakrania A; Aubé M; Desjardins R; Sabbagh R; Day R
Can J Physiol Pharmacol; 2020 Jul; 98(7):477-481. PubMed ID: 32119574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
